

Kosei Hasegawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3307128/publications.pdf>

Version: 2024-02-01

38
papers

787
citations

623734

14
h-index

552781

26
g-index

38
all docs

38
docs citations

38
times ranked

1240
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. <i>Gynecologic Oncology</i> , 2018, 151, 381-389. | 1.4 | 99 |
| 2 | Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). <i>Journal of Clinical Oncology</i> , 2021, 39, 3671-3681. | 1.6 | 84 |
| 3 | Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. <i>Nature Communications</i> , 2019, 10, 4965. | 12.8 | 82 |
| 4 | T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6110-6117. | 7.0 | 63 |
| 5 | Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. <i>Oncolmmunology</i> , 2015, 4, e1030561. | 4.6 | 52 |
| 6 | Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma. <i>Modern Pathology</i> , 2019, 32, 1023-1031. | 5.5 | 35 |
| 7 | MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. <i>Oncotarget</i> , 2016, 7, 75328-75338. | 1.8 | 33 |
| 8 | Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 145, 78-87. | 1.4 | 31 |
| 9 | Association of histone deacetylase expression with histology and prognosis of ovarian cancer. <i>Oncology Letters</i> , 2018, 15, 3524-3531. | 1.8 | 29 |
| 10 | Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations. <i>Investigational New Drugs</i> , 2017, 35, 800-812. | 2.6 | 23 |
| 11 | Systematic Identification of Characteristic Genes of Ovarian Clear Cell Carcinoma Compared with High-Grade Serous Carcinoma Based on RNA-Sequencing. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4330. | 4.1 | 21 |
| 12 | Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 2397. | 3.3 | 21 |
| 13 | Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 144, 329-335. | 1.4 | 20 |
| 14 | Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. <i>Journal of Surgical Oncology</i> , 2018, 117, 488-496. | 1.7 | 15 |
| 15 | Hormonal Regulation of Patient-Derived Endometrial Cancer Stem-like Cells Generated by Three-Dimensional Culture. <i>Endocrinology</i> , 2019, 160, 1895-1906. | 2.8 | 15 |
| 16 | Significance of venous thromboembolism in women with uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2018, 148, 267-274. | 1.4 | 14 |
| 17 | Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 3676-3684. | 1.5 | 14 |
| 18 | Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. <i>Surgical Oncology</i> , 2018, 27, 433-440. | 1.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e25. | 2.2 | 11 |
| 20 | Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from <sc>KEYNOTE</sc>â€826. <i>Cancer Science</i> , 2022, 113, 3877-3887. | 3.9 | 11 |
| 21 | Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 147, 565-571. | 1.4 | 9 |
| 22 | Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 331-339. | 1.4 | 9 |
| 23 | Current and future strategies for treatment of ovarian clear cell carcinoma. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 1678-1689. | 1.3 | 9 |
| 24 | Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. <i>Supportive Care in Cancer</i> , 2014, 22, 2891-2898. | 2.2 | 8 |
| 25 | Immunogenomic landscape of gynecologic carcinosarcoma. <i>Gynecologic Oncology</i> , 2021, 160, 547-556. | 1.4 | 8 |
| 26 | Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e16. | 2.2 | 8 |
| 27 | High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e93. | 2.2 | 8 |
| 28 | Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e21. | 2.2 | 7 |
| 29 | Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , 2019, 8, 200. | 4.1 | 6 |
| 30 | Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients. <i>Endocrine Journal</i> , 2020, 67, 219-229. | 1.6 | 6 |
| 31 | Long Intergenic Noncoding RNA OIN1 Promotes Ovarian Cancer Growth by Modulating Apoptosis-Related Gene Expression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11242. | 4.1 | 6 |
| 32 | Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 2756-2766. | 1.5 | 5 |
| 33 | Clinical utility of CA-125 in the management of uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e88. | 2.2 | 4 |
| 34 | Transcriptomic analysis of hormone-sensitive patient-derived endometrial cancer spheroid culture defines Efp as a proliferation modulator. <i>Biochemical and Biophysical Research Communications</i> , 2021, 548, 204-210. | 2.1 | 3 |
| 35 | Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma. <i>BMC Cancer</i> , 2022, 22, 59. | 2.6 | 3 |
| 36 | Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 689. | 4.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years. Surgical Oncology, 2019, 29, 25-32. | 1.6 | 1 |
| 38 | Adjuvant chemotherapy in patients with uterine carcinosarcoma: a review of clinical outcomes and considerations. Expert Opinion on Orphan Drugs, 2021, 9, 247-255. | 0.8 | 0 |